Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Henry Bryant
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Living Beings
Procedures
Anatomy
Concepts & Ideas
Physiology
Sign-in to see full Profile
Network (preview)
23
Sato, Masahiko
12
Glasebrook, Andrew
11
Dodge, Jeffrey
10
Adrian, Mary
10
Magee, David
9
Ma, Yanfei
8
Short, LL
7
Onyia, Jude
7
Phillips, DL
7
Cole, Harlan
7
Geiser, Andrew
6
Halladay, David
6
Shetler, Pamela
6
Wei, Tao
6
Holaday, John
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Henry Bryant (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2008: Farr T D; Carswell H V O; McCann D J; Sato M; Bryant H U; Dodge J A; Macrae I M
The selective oestrogen receptor modulator, LY362321, is not neuroprotective in a rat model of transient focal ischaemia.
Journal of neuroendocrinology 2008;20(3):366-74.
-
2007: Kulkarni Nalini H; Wei Tao; Kumar Amar; Dow Ernst R; Stewart Trent R; Shou Jianyong; N'cho Mathias; Sterchi Diane L; Gitter Bruce D; Higgs Richard E; Halladay David L; Engler Thomas A; Martin T John; Bryant Henry U; Ma Yanfei L; Onyia Jude E
Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor.
Journal of cellular biochemistry 2007;102(6):1504-18.
-
2007: Richardson Timothy I; Frank Scott A; Wang Minmin; Clarke Christian A; Jones Scott A; Ying Bai-Ping; Kohlman Dan T; Wallace Owen B; Shepherd Timothy A; Dally Robert D; Palkowitz Alan D; Geiser Andrew G; Bryant Henry U; Henck Judith W; Cohen Ilene R; Rudmann Daniel G; McCann Denis J; Coutant David E; Oldham Samuel W; Hummel Conrad W; Fong Kin C; Hinklin Ronald; Lewis George; Tian Hongqi; Dodge Jeffrey A
Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety.
Bioorganic & medicinal chemistry letters 2007;17(13):3544-9.
-
2007: Wei Tao; Geiser Andrew G; Qian Hui-Rong; Su Chen; Helvering Leah M; Kulkarini Nalini H; Shou Jianyong; N'Cho Mathias; Bryant Henry U; Onyia Jude E
DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids.
BMC women's health 2007;7():5.
-
2006: Kulkarni Nalini H; Onyia Jude E; Zeng Qingqiang; Tian Xioayan; Liu Min; Halladay David L; Frolik Charles A; Engler Thomas; Wei Tao; Kriauciunas Aidas; Martin T John; Sato Masahiko; Bryant Henry U; Ma Yanfei L
Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2006;21(6):910-20.
-
2006: Krishnan Venkatesh; Bryant Henry U; Macdougald Ormond A
Regulation of bone mass by Wnt signaling.
The Journal of clinical investigation 2006;116(5):1202-9.
-
2006: Wallace Owen B; Lauwers Kenneth S; Dodge Jeffrey A; May Scott A; Calvin Joel R; Hinklin Ronald; Bryant Henry U; Shetler Pamela K; Adrian Mary D; Geiser Andrew G; Sato Masahiko; Burris Thomas P
A selective estrogen receptor modulator for the treatment of hot flushes.
Journal of medicinal chemistry 2006;49(3):843-6.
-
2005: Hummel Conrad W; Geiser Andrew G; Bryant Henry U; Cohen Ilene R; Dally Robert D; Fong Kin Chiu; Frank Scott A; Hinklin Ronald; Jones Scott A; Lewis George; McCann Denis J; Rudmann Daniel G; Shepherd Timothy A; Tian Hongqi; Wallace Owen B; Wang Minmin; Wang Yong; Dodge Jeffrey A
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
Journal of medicinal chemistry 2005;48(22):6772-5.
-
2005: Helvering Leah M; Liu Riting; Kulkarni Nalini H; Wei Tao; Chen Peining; Huang Shuguang; Lawrence Frank; Halladay David L; Miles Rebecca R; Ambrose Emily M; Sato Masahiko; Ma Yanfei L; Frolik Charles A; Dow Ernst R; Bryant Henry U; Onyia Jude E
Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene.
Molecular pharmacology 2005;68(5):1225-38.
-
2005: Geiser Andrew G; Hummel Conrad W; Draper Michael W; Henck Judith W; Cohen Ilene R; Rudmann Daniel G; Donnelly Kevin B; Adrian Mary D; Shepherd Timothy A; Wallace Owen B; McCann Denis J; Oldham Samuel W; Bryant Henry U; Sato Masahiko; Dodge Jeffrey A
A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation.
Endocrinology 2005;146(10):4524-35.
-
2005: Chintalacharuvu S; Evans G F; Shih C; Bryant H U; Sandusky G E; Zuckerman S H
Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis.
Clinical and experimental rheumatology 2005;23(4):438-46.
-
2005: Onyia Jude E; Helvering Leah M; Gelbert Lawrence; Wei Tao; Huang Shuguang; Chen Peining; Dow Ernst R; Maran Avudaiappan; Zhang Minzhi; Lotinun Sutada; Lin Xi; Halladay David L; Miles Rebecca R; Kulkarni Nalini H; Ambrose Emily M; Ma Yanfei L; Frolik Charles A; Sato Masahiko; Bryant Henry U; Turner Russell T
Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray.
Journal of cellular biochemistry 2005;95(2):403-18.
-
2005: Helvering L M; Adrian M D; Geiser A G; Estrem S T; Wei T; Huang S; Chen P; Dow E R; Calley J N; Dodge J A; Grese T A; Jones S A; Halladay D L; Miles R R; Onyia J E; Ma Y L; Sato M; Bryant H U
Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus.
Biology of reproduction 2005;72(4):830-41.
-
2005: Krishnan V; Bullock H A; Yaden B C; Liu M; Barr R J; Montrose-Rafizadeh C; Chen K; Dodge J A; Bryant H U
The nongenotropic synthetic ligand 4-estren-3alpha17beta-diol is a high-affinity genotropic androgen receptor agonist.
Molecular pharmacology 2005;67(3):744-8.
-
2005: Ma Yanfei L; Bryant Henry U; Zeng Qingqiang; Schmidt Allen; Jee Webster S S; Sato Masahiko
Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats.
Journal of bone and mineral metabolism 2005;23 Suppl():62-8.
-
2004: Wallace Owen B; Bryant Henry U; Shetler Pamela K; Adrian Mary D; Geiser Andrew G
Benzothiophene and naphthalene derived constrained SERMs.
Bioorganic & medicinal chemistry letters 2004;14(20):5103-6.
-
2004: Sporn Michael B; Dowsett Sherie A; Mershon John; Bryant Henry U
Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action.
Clinical therapeutics 2004;26(6):830-40.
-
2004: Onyia Jude E; Galvin Rachelle J Sells; Ma Yanfei L; Halladay David L; Miles Rebecca R; Yang Xuhao; Fuson Tina; Cain Ricky L; Zeng Qing Qiang; Chandrasekhar S; Emkey Renee; Xu Yanping; Thirunavukkarasu Kannan; Bryant Henry U; Martin T John
Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption.
The Journal of pharmacology and experimental therapeutics 2004;309(1):369-79.
-
2003: Lugar Charles W; Magee David; Adrian Mary D; Shetler Pamela; Bryant Henry U; Dodge Jeffrey A
B-ring unsaturated estrogens: biological evaluation of 17alpha-Dihydroequilein and novel B-Nor-6-thiaequilenins as tissue selective estrogens.
Bioorganic & medicinal chemistry letters 2003;13(24):4281-4.
-
2003: Ma Yanfei L; Bryant Henry U; Zeng Qingqiang; Schmidt Allen; Hoover Jennifer; Cole Harlan W; Yao Wei; Jee Webster S S; Sato Masahiko
New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.
Endocrinology 2003;144(5):2008-15.
-
2002: Ma Yanfei L; Bryant Henry U; Zeng Qingqiang; Palkowitz Alan; Jee Webster S S; Turner Charles H; Sato Masahiko
Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2002;17(12):2256-64.
-
2002: Bryant Henry U
Selective estrogen receptor modulators.
Reviews in endocrine & metabolic disorders 2002;3(3):231-41.
-
2001: Suh N; Glasebrook A L; Palkowitz A D; Bryant H U; Burris L L; Starling J J; Pearce H L; Williams C; Peer C; Wang Y; Sporn M B
Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
Cancer research 2001;61(23):8412-5.
-
2001: Grese T A; Adrian M D; Phillips D L; Shetler P K; Short L L; Glasebrook A L; Bryant H U
Photochemical synthesis of N-arylbenzophenanthridine selective estrogen receptor modulators (serms).
Journal of medicinal chemistry 2001;44(17):2857-60.
-
2001: Bryant H U
Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation.
Reviews in endocrine & metabolic disorders 2001;2(1):129-38.
-
2000: Bryant H U; Fukuyama T; Nakazawa T
[Raloxifene mimics the effect of estrogen on bone]
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme 2000;45(6 Suppl):1102-8.
-
2000: Krishnan V; Heath H; Bryant H U
Mechanism of action of estrogens and selective estrogen receptor modulators.
Vitamins and hormones 2000;60():123-47.
-
1999: Wu X; Glinn M A; Ostrowski N L; Su Y; Ni B; Cole H W; Bryant H U; Paul S M
Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats.
Brain research 1999;847(1):98-104.
-
1999: Bryant H U; Glasebrook A L; Yang N N; Sato M
An estrogen receptor basis for raloxifene action in bone.
The Journal of steroid biochemistry and molecular biology 1999;69(1-6):37-44.
-
1999: Sato M; Grese T A; Dodge J A; Bryant H U; Turner C H
Emerging therapies for the prevention or treatment of postmenopausal osteoporosis.
Journal of medicinal chemistry 1999;42(1):1-24.
-
1998: Sato M; Turner C H; Wang T; Adrian M D; Rowley E; Bryant H U
LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
The Journal of pharmacology and experimental therapeutics 1998;287(1):1-7.
-
1998: Turner R T; Evans G L; Sluka J P; Adrian M D; Bryant H U; Turner C H; Sato M
Differential responses of estrogen target tissues in rats including bone to clomiphene, enclomiphene, and zuclomiphene.
Endocrinology 1998;139(9):3712-20.
-
1998: Bryant H U; Kauffman R F; Iversen P; Cox D A; Mitlak B H; Heath H
Comment on lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys.
The Journal of clinical endocrinology and metabolism 1998;83(8):3001-4.
-
1998: Grese T A; Pennington L D; Sluka J P; Adrian M D; Cole H W; Fuson T R; Magee D E; Phillips D L; Rowley E R; Shetler P K; Short L L; Venugopalan M; Yang N N; Sato M; Glasebrook A L; Bryant H U
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Journal of medicinal chemistry 1998;41(8):1272-83.
-
1998: Bryant H U; Dere W H
Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1998;217(1):45-52.
-
1997: Grese T A; Sluka J P; Bryant H U; Cullinan G J; Glasebrook A L; Jones C D; Matsumoto K; Palkowitz A D; Sato M; Termine J D; Winter M A; Yang N N; Dodge J A
Molecular determinants of tissue selectivity in estrogen receptor modulators.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(25):14105-10.
-
1997: Hol T; Cox M B; Bryant H U; Draper M W
Selective estrogen receptor modulators and postmenopausal women's health.
Journal of women's health / the official publication of the Society for the Advancement of Women's Health Research 1997;6(5):523-31.
-
1997: Palkowitz A D; Glasebrook A L; Thrasher K J; Hauser K L; Short L L; Phillips D L; Muehl B S; Sato M; Shetler P K; Cullinan G J; Pell T R; Bryant H U
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
Journal of medicinal chemistry 1997;40(10):1407-16.
-
1997: Jimenez M A; Magee D E; Bryant H U; Turner R T
Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats.
Endocrinology 1997;138(5):1794-800.
-
1997: Dodge J A; Lugar C W; Cho S; Short L L; Sato M; Yang N N; Spangle L A; Martin M J; Phillips D L; Glasebrook A L; Osborne J J; Frolik C A; Bryant H U
Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.
The Journal of steroid biochemistry and molecular biology 1997;61(1-2):97-106.
-
1997: Bowling N; Bloomquist W E; Cohen M L; Bryant H U; Cole H W; Magee D E; Rowley E R; Vlahos C J
Effects of prolonged ethinyl estradiol treatment on calcium channel binding and in vivo calcium-mediated hemodynamic responses in ovariectomized rats.
The Journal of pharmacology and experimental therapeutics 1997;281(1):218-25.
-
1997: Grese T A; Cho S; Finley D R; Godfrey A G; Jones C D; Lugar C W; Martin M J; Matsumoto K; Pennington L D; Winter M A; Adrian M D; Cole H W; Magee D E; Phillips D L; Rowley E R; Short L L; Glasebrook A L; Bryant H U
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Journal of medicinal chemistry 1997;40(2):146-67.
-
1997: Kauffman R F; Bensch W R; Roudebush R E; Cole H W; Bean J S; Phillips D L; Monroe A; Cullinan G J; Glasebrook A L; Bryant H U
Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator.
The Journal of pharmacology and experimental therapeutics 1997;280(1):146-53.
-
1996: Dodge J A; Glasebrook A L; Magee D E; Phillips D L; Sato M; Short L L; Bryant H U
Environmental estrogens: effects on cholesterol lowering and bone in the ovariectomized rat.
The Journal of steroid biochemistry and molecular biology 1996;59(2):155-61.
-
1996: Evans G L; Bryant H U; Magee D E; Turner R T
Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia.
Endocrinology 1996;137(10):4139-44.
-
1996: Frolik C A; Bryant H U; Black E C; Magee D E; Chandrasekhar S
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Bone 1996;18(6):621-7.
-
1996: Sato M; Rippy M K; Bryant H U
Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1996;10(8):905-12.
-
1996: Yang N N; Bryant H U; Hardikar S; Sato M; Galvin R J; Glasebrook A L; Termine J D
Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance.
Endocrinology 1996;137(5):2075-84.
-
1996: Sato M; Bryant H U; Dodge J A; Davis H; Matter W F; Vlahos C J
Effects of wortmannin analogs on bone in vitro and in vivo.
The Journal of pharmacology and experimental therapeutics 1996;277(1):543-50.
-
1996: Bryant H U; Nelson D L; Button D; Cole H W; Baez M B; Lucaites V L; Wainscott D B; Whitesitt C; Reel J; Simon R; Koppel G A
A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines.
Life sciences 1996;59(15):1259-68.
-
1995: Fuchs-Young R; Glasebrook A L; Short L L; Draper M W; Rippy M K; Cole H W; Magee D E; Termine J D; Bryant H U
Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor.
Annals of the New York Academy of Sciences 1995;761():355-60.
-
1995: Sato M; Kim J; Short L L; Slemenda C W; Bryant H U
Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats.
The Journal of pharmacology and experimental therapeutics 1995;272(3):1252-9.
-
1995: Cole H W; Brown C E; Magee D E; Magee C; Roudebush R E; Bryant H U
Serotonin-induced paw edema in the rat: pharmacological profile.
General pharmacology 1995;26(2):431-6.
-
1994: Evans G; Bryant H U; Magee D; Sato M; Turner R T
The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
Endocrinology 1994;134(5):2283-8.
-
1994: Sato M; McClintock C; Kim J; Turner C H; Bryant H U; Magee D; Slemenda C W
Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1994;9(5):715-24.
-
1993: Roudebush R E; Bryant H U
Pharmacologic manipulation of a four day murine delayed type hypersensitivity model.
Agents and actions 1993;38(1-2):116-21.
-
1992: Mitlak B H; Williams D C; Bryant H U; Paul D C; Neer R M
Intermittent administration of bovine PTH-(1-34) increases serum 1,25-dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1992;7(5):479-84.
-
1992: Roudebush R E; Bryant H U
Pharmacologic manipulation of graft versus host induced splenomegaly.
Agents and actions 1992;35(3-4):260-7.
-
1991: Roudebush R E; Bryant H U
Conditioned immunosuppression of a murine delayed type hypersensitivity response: dissociation from corticosterone elevation.
Brain, behavior, and immunity 1991;5(3):308-17.
-
1991: Bryant H U; Bernton E W; Kenner J R; Holaday J W
Role of adrenal cortical activation in the immunosuppressive effects of chronic morphine treatment.
Endocrinology 1991;128(6):3253-8.
-
1991: Roudebush R E; Berry P L; Layman N K; Butler L D; Bryant H U
Dissociation of immunosuppression by chlorpromazine and trifluoperazine from pharmacologic activities as dopamine antagonists.
International journal of immunopharmacology 1991;13(7):961-8.
-
1990: Bryant H U; Roudebush R E
Suppressive effects of morphine pellet implants on in vivo parameters of immune function.
The Journal of pharmacology and experimental therapeutics 1990;255(2):410-4.
-
1990: Bryant H U; Bernton E W; Holaday J W
Immunomodulatory effects of chronic morphine treatment: pharmacologic and mechanistic studies.
NIDA research monograph 1990;96():131-49.
-
1989: Bryant H U; Holaday J W; Bernton E W
Cysteamine produces dose-related bidirectional immunomodulatory effects in mice.
The Journal of pharmacology and experimental therapeutics 1989;249(2):424-9.
-
1988: Bryant H U; Bernton E W; Holaday J W
Morphine pellet-induced immunomodulation in mice: temporal relationships.
The Journal of pharmacology and experimental therapeutics 1988;245(3):913-20.
-
1988: Bryant H U; Yoburn B C; Inturrisi C E; Bernton E W; Holaday J W
Morphine-induced immunomodulation is not related to serum morphine concentrations.
European journal of pharmacology 1988;149(1-2):165-9.
-
1987: Bryant H U; Bernton E W; Holaday J W
Immunosuppressive effects of chronic morphine treatment in mice.
Life sciences 1987;41(14):1731-8.
Sign-in to see more
